News Releases

Date	Title and Summary	View
June 5, 2021	KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop – KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 5, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the...	Additional Formats PDF Version
May 27, 2021	KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 27, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a...	Additional Formats PDF Version
May 10, 2021	KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 10, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an...	Additional Formats PDF Version
May 3, 2021	KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 3, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul...	Additional Formats PDF Version
April 20, 2021	KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824 – KVD824 Phase 2 on Clinical Hold – – Planning for KVD900 Phase 3 Unaffected – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 20, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization...	Additional Formats PDF Version
March 19, 2021	KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Mar. 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has...	Additional Formats PDF Version
March 11, 2021	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results – Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offering, Funded to KVD900 NDA Filing – CAMBRIDGE, Mass....	Additional Formats PDF Version
February 18, 2021	KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 18, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in...	Additional Formats PDF Version
February 16, 2021	KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before...	Additional Formats PDF Version
February 10, 2021	KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share....	Additional Formats PDF Version